The influence of atypical antipsychotic drugs on sexual function

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 1655-1661

  Just, Marek J ^a  

^a Department of General and Endocronological Surgery Piekary Medical Centre   (Poland)

Author keywords

Anorgasmia; Galactorrhea; Hyperprolactinemia; Mood disorders; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE; NORADRENALIN; PROLACTIN; SEROTONIN;

ADRENERGIC SYSTEM; CENTRAL NERVOUS SYSTEM; DISEASE ASSOCIATION; DOPAMINE METABOLISM; DOPAMINE RELEASE; HUMAN; HYPERPROLACTINEMIA; MEDICATION COMPLIANCE; PROLACTIN RELEASE; QUALITY OF LIFE; REVIEW; SEDATION; SELF ESTEEM; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; UNSPECIFIED SIDE EFFECT;

EID: 84937546703     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S84528     Document Type: Review

References (59)

1. Grover S, Ghosh A, Sarkar S, Chakrabarti S, Avasthi A. Sexual dysfunction in clinically stable patients with bipolar disorder receiving lithium. J Clin Psychopharmacol. 2014;34(4):475-482.
2. Hamilton LD, Meston CM. Chronic stress and sexual function in women. J Sex Med. 2013;10(10):2443-2454.
3. Agmo A. On the intricate relationship between sexual motivation and arousal. Horm Behav. 2011;59(5):681-688.
4. Boin AC, Nozoe KT, Polesel DN, Andersen ML, Tufik S. The potential role of sleep in sexual dysfunction in patients with schizophrenia. Schizophr Res. 2014;154(1-3):126-127.
5. Kopecek M, Bares M, Svarc J, Dockery C, Horacek J. Hyperprolactinemia after low dose of amisulpride. Neuro Endocrinol Lett. 2004;25(6):419-422.
6. Oglodek E, Szota A, Araszkiewicz A. Electroconvulsive therapy in a patient with drug-resistant depression and thyroid hormone imbalance. Aust N Z J Psychiatry. 2014;48(1):96-97.
7. Oglodek E, Wiczkowski A, Sieron A, Bilska-Urban A, Moś D. The effect of extremely low-frequency magnetic fields on the morphology of thyroid gland cells in female rats. Pol J Environ Stud. 2008;17(5):757-763.
8. Kristensen D, Hageman I, Bauer J, Jørgensen MB, Correll CU. Antipsychotic polypharmacy in a treatment-refractory schizophrenia population receiving adjunctive treatment with electroconvulsive therapy. J ECT. 2013;29(4):271-276.
9. Millier A, Amri I, Boyer L, Auquier P, Toumi M. Utility decrements associated with side effects in schizophrenia. J Med Econ. 2014;17(12):853-861.
10. Connolly A, Taylor D. Factors associated with non evidence-based prescribing of antipsychotics. Ther Adv Psychopharmacol. 2014;4(6):247-256.
11. Oglodek E, Szota A, Araszkiewicz A. Olanzapine-induced neuroleptic malignant syndrome after 10 years of treatment. Aust N Z J Psychiatry. 2013;47(10):972.
12. Szota A, Ogłodek E, Araszkiewicz A. Fever development in neuroleptic malignant syndrome during treatment with olanzapine and clozapine. Pharmacol Rep. 2013;65(2):279-287.
13. Grundmann M, Kacirova I, Urinovska R. Therapeutic drug monitoring of atypical antipsychotic drugs. Acta Pharm. 2014;64(4):387-401.
14. Szota A, Oglodek E, Araszkiewicz A. A female patient with depression and conversion disorder following brain tumor surgery. Aust N Z J Psychiatry. 2013;47(12):1213-1214.
15. Szota A, Ogłodek E, Araszkiewicz A. Bipolar disorder: mixed episodes concomitant with gambling addiction. Aust N Z J Psychiatry. 2013;48(6):586-587.
16. Gründer G, Wetzel H, Schlösser R, et al. Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry. 1999;45(1):89-97.
17. Bevan JS. Interpreting prolactin levels: implications for the management of large pituitary lesions. Br J Neurosurg. 1991;5(1):3-6.
18. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80(4):1523-1631.
19. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291-2314.
20. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28(suppl 2):55-68.
21. Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421-453.
22. Weizmann A, Weizmann R, Hart J, Maoz B, Wijsenbeek H, Ben David M. The correlation of increased serum prolactin levels with decreased sexual desire and activity in elderly men. J Am Geriatr Soc. 1983;31(8):485-488.
23. Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013;11:CD006625.
24. Suzuki Y, Sugai T, Fukui N, et al. Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics. Schizophr Res. 2013;145(1-3):116-119.
25. Jeong HG, Lee MS, Lee HY, Ko YH, Han C, Joe SH. Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study. Int Clin Psychopharmacol. 2012;27(4):177-183.
26. Buckley PF, Goldstein JM, Emsley RA. Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schizophr Res. 2004;66(2-3):143-150.
27. Jummani R, Coffey BJ. Hyperprolactinemia in an adolescent with psychotic disorder on risperidone. J Child Adolesc Psychopharmacol. 2009;19(6):791-794.
28. Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol. 2011;26(3):130-140.
29. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000;22(9):1085-1096.
30. Konarzewska B, Wołczyński S, Szulc A, Galińska B, Popławska R, Waszkiewicz N. Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology. 2009;34(1):129-139.
31. Kim KS, Pae CU, Chae JH, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry. 2002;63(5):408-413.
32. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol. 2008;23(3):201-209.
33. Martin-Du PR, Baumann P. Sexual dysfunctions induced by antidepressants and antipsychotics. Rev Med Suisse. 2008;4(150):758-762.
34. Muscatello MR, Bruno A, Pandolfo G, Micò U, Settineri S, Zoccali R. Emerging treatments in the management of schizophrenia - focus on sertindole. Drug Des Devel Ther. 2010;4:187-201.
35. Lewis R, Bagnall A, Leitner M. Sertindole for schizophrenia. Cochrane Database Syst Rev. 2000;(2):CD001715.
36. Jukić MK, Drmić S, Mimica N. Ejaculatory dysfunction in patient with schizophrenia on sertindole. Psychiatr Danub. 2010;22(1):128-131.
37. Crawford AM, Beasley CM Jr, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res. 1997;26(1):41-54.
38. Ogłodek EA, Szota A, Just MJ, Moś D, Araszkiewicz A. Comparison of chemokines (CCL-5 and SDF-1), chemokine receptors (CCR-5 and CXCR-4) and IL-6 levels in patients with different severities of depression. Pharmacol Rep. 2014;66(5):920-926.
39. Ogłodek EA, Szota AM, Just MJ, Moś DM, Araszkiewicz A. The MCP-1, CCL-5 and SDF-1 chemokines as pro-inflammatory markers in generalized anxiety disorder and personality disorders. Pharmacol Rep. 2015;67(1):85-89.
40. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol. 1999;19(1):57-61.
41. Breier AF, Malhotra AK, Su TP, Pinals DA, Elman I, Adler CM. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry. 1999;156(2):294-298.
42. Pérez-Iglesias R, Mata I, Martínez-García O, et al. Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis. J Clin Psychopharmacol. 2012;32(6):804-808.
43. Doufik J, Otheman Y, Khalili L, Ghanmi J, Ouanass A. Antipsychotic-induced priapism and management challenges: a case report. Encephale. 2014;40(6):518-521.
44. Penaskovic KM, Haq F, Raza S. Priapism during treatment with olanzapine, quetiapine, and risperidone in a patient with schizophrenia: a case report. Prim Care Companion J Clin Psychiatry. 2010;12(5). PCC.09l00939.
45. Jagadheesan K, Thakur A, Akhtar S. Irreversible priapism during olanzapine and lithium therapy. Aust N Z J Psychiatry. 2004;38(5):381.
46. Ginory A, Nguyen M. A case of priapism with risperidone. Case Rep Psychiatry. 2014;2014:241573.
47. Cruzado L, Vallejos CE. Priapism associated with risperidone use: report of one case. Rev Med Chil. 2012;140(11):1445-1448.
48. Karamustafalioglu N, Kalelioglu T, Tanriover O, Gungor F, Genc A. A case report of priapism caused by ziprasidon. Psychiatry Investig. 2003;10(4):425-427.
49. Kaufman KR, Stern L, Mohebati A, Olsavsky A, Hwang J. Ziprasidone-induced priapism requiring surgical treatment. Eur Psychiatry. 2006;21(1):48-50.
50. Denton K, Kolli V, Sharma A. Ziprasidone-induced ischemic priapism requiring surgical intervention: a case report. Prim Care Companion CNS Disord. 2013;15(1). PCC.12l01443.
51. Prabhuswamy M, Srinath S, Girimaji S, Seshadri S. Risperidone-induced priapism in a 12-year-old boy with schizophrenia. J Child Adolesc Psychopharmacol. 2007;17(4):539-540.
52. Husár M, Zerhau P. Priapism in childhood-case report of 14-year-old boy. Rozhl Chir. 2006;85(7):329-330.
53. Brichart N, Delavierre D, Peneau M, Ibrahim H, Mallek A. Priapism associated with antipsychotic medications: a series of four patients. Prog Urol. 2008;18(10):669-673.
54. Reeves RR, Kimble R. Prolonged erections associated with ziprasidone treatment: a case report. J Clin Psychiatry. 2003;64(1):97-98.
55. Mitchell JE, Popkin MK. Antipsychotic drug therapy and sexual dysfunction in men. Am J Psychiatry. 1982;139(5):633-637.
56. Songer DA, Barclay JC. Olanzapine-induced priapism. Am J Psychiatry. 2001;158(12):2087-2088.
57. Shah SK. A comparative study of sexual dysfunction in schizophrenia patients taking aripiprazole versus risperidone. Kathmandu Univ Med J. 2013;11(42):121-125.
58. Andersohn F, Schmedt N, Weinmann S, Willich SN, Garbe E. Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity. J Clin Psychopharmacol. 2010;30(1):68-71.
59. Ogłodek E, Szota A, Just M, Moś D, Araszkiewicz A. The role of the neuroendocrine and immune systems in the pathogenesis of depression. Pharmacol Rep. 2014;66(5):776-781.